Diversified Trust Co Invests $2.17 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Diversified Trust Co acquired a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 34,553 shares of the biotechnology company’s stock, valued at approximately $2,166,000.

Several other hedge funds have also recently made changes to their positions in the company. Corient Private Wealth LLC lifted its position in Arrowhead Pharmaceuticals by 3.1% during the 4th quarter. Corient Private Wealth LLC now owns 18,226 shares of the biotechnology company’s stock worth $1,210,000 after acquiring an additional 551 shares during the period. Bank of Hawaii purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at about $1,276,000. Invesco Ltd. increased its holdings in shares of Arrowhead Pharmaceuticals by 8.9% in the fourth quarter. Invesco Ltd. now owns 547,758 shares of the biotechnology company’s stock valued at $36,366,000 after purchasing an additional 44,866 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at about $352,000. Finally, Summit Global Investments raised its stake in shares of Arrowhead Pharmaceuticals by 43.8% in the fourth quarter. Summit Global Investments now owns 14,287 shares of the biotechnology company’s stock worth $949,000 after purchasing an additional 4,353 shares during the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ARWR has been the subject of a number of research reports. Leerink Partners lifted their target price on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a report on Wednesday, June 17th. Morgan Stanley upgraded shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $78.00 to $100.00 in a report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. Sanford C. Bernstein lifted their price objective on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $86.36.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $81.82 on Monday. The firm has a market capitalization of $11.53 billion, a P/E ratio of -38.06 and a beta of 1.28. The stock has a 50-day simple moving average of $74.25 and a two-hundred day simple moving average of $67.76. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $14.30 and a fifty-two week high of $84.55.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.17. The firm had revenue of $73.74 million for the quarter, compared to the consensus estimate of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The company’s revenue was down 86.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.75 earnings per share. On average, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3 earnings per share for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director Hongbo Lu sold 2,970 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the sale, the director owned 52,012 shares of the company’s stock, valued at $3,998,682.56. This trade represents a 5.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer directly owned 162,905 shares of the company’s stock, valued at approximately $11,623,271.75. This trade represents a 7.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 26,065 shares of company stock valued at $1,912,662. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.